Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3056% above fair value
$30.52+0.57 (+1.90%)
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Cibinqo (abrocitinib by Quarter
Cibinqo (abrocitinib — atopic dermatitis) — Worldwide reported YoY (%) (%)
Pfizer Cibinqo (abrocitinib: 38.0% in Q2 2026, down 9.0 pts from a year earlier.
Latest, Q2 2026
38.0%
Period ended Jun 28, 2026
Change on a year earlier
-9.0 pts
47.0% in Q2 2025
History
9 quarters
Since Q2 2024
Sources
9
Documents cited below
Where the Q2 2026 figure comes from
“|| Cibinqo | 94 | 69 | 38% | 34% | 34 | 24 | 39% | 61 | 44 | 37% | 32%”
Source: Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Reported in Form 8-K Revenue Tables.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Pfizer Cibinqo (abrocitinib (%), quarterly Q2 2024–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/cibinqo-yoy-ww
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.